Publications
VST Cells
G-Rex®24 Well Plate
Publication Date: January 30, 2024
Virus-positive Merkel cell carcinoma patients who responded to PD-1 blockade showed a broader and larger T antigen–specific CD8+ T cell response in blood than nonresponders. Using DNA-barcoded pMHC multimers covering 33 HLA class I haplotypes, the authors screened 26 patients treated with pembrolizumab and detected T cell recognition of 32 T antigen epitopes, 20 previously unreported. Responders (n = 17) gained more T antigen–specific populations after treatment than nonresponders (n = 7). In a second cohort of 19 patients, antigen-presenting scaffolds expanded T antigen–specific T cells in 13 patients, with an average 214-fold increase over 14 days. Expanded cells killed HLA-matched Merk…
Publications
CAR T Cells
Publication Date: January 26, 2024
In the Tmod two-receptor system, blocker function depends on the height of the blocker antigen above the target cell membrane, and receptor hinge length can compensate for mismatched antigen pairs. Jurkat cells carrying a CD19 activator were inhibited approximately 90% by an HLA-A*02 blocker (55Å), but only 40% by a mesothelin blocker (90Å) and 20% by an ICAM-1 blocker (185Å). Blockers against membrane-proximal mesothelin epitopes inhibited more strongly than membrane-distal ones (Imax ~70% vs 50%; IC50 ~60 ng vs 250 ng mRNA). Using EGF-like hinge repeats, long activators paired with short blockers gave the best selectivity, and primary T cells in that configuration completely spared CD19…
Publications
CAR T Cells
Publication Date: January 25, 2024
Adding inosine to culture medium during manufacturing gave human CAR-T cells a stem-like, more potent profile, whereas knocking out CD39, CD73 or the adenosine receptor A2aR changed them only modestly. Overexpressing adenosine deaminase, which converts adenosine to inosine, shifted exhausted GD2 CAR-T cells toward stem-like memory states, and inosine alone reproduced this in vitro with higher CD62L, greater cytokine release and cytotoxicity. Inosine lowered glycolysis, raised glutaminolysis and polyamine synthesis, increased chromatin accessibility at stemness genes, and its stemness effect was lost after EIF5A knockout. In a clinical-scale GD2-CAR run in a semi-closed G-Rex® system, inos…
Publications
CAR T Cells, DC Cells, TIL Cells
Publication Date: January 15, 2024
Autologous cell therapies for cancer fall into four classes: CAR T cells, tumor-infiltrating lymphocytes, dendritic cell vaccines and whole tumor cell vaccines. Each class faces distinct engineering hurdles. CAR T cells need efficient, multiplexed gene editing and more consistent products, while TIL therapy needs simpler, faster manufacturing and less exhaustion. DC vaccines require better cell sources, antigen loading and lymph node trafficking, and tumor cell vaccines need wider patient eligibility and consistent genetic modification. Across all four, the review identifies long manufacturing times, specialized expansion processes, quality control, trafficking, and toxicity from cytokine…
Publications
Treg Cells
G-Rex®24 Well Plate
Publication Date: January 8, 2024
Ex vivo-expanded, amyloid-β-specific regulatory T cells improved memory and reduced Alzheimer's-type pathology in 5xFAD mice, with benefits at doses as low as 1.5 × 10^3 cells per mouse. Splenocytes from C57BL/6 mice, depleted of CD8 cells, were exposed for four days to fibrillized Aβ and bee venom phospholipase A2; CD4+CD25+ Tregs were then isolated at over 97% purity and expanded for two weeks in a G-Rex® 24-well plate with CD3/CD28 beads and 2000 U/mL IL-2. Eight weeks after intravenous transfer, treated mice showed better Y-maze alternation and passive-avoidance latency, less hippocampal Aβ, phosphorylated tau and NOS2, lower pro-inflammatory transcripts and a stronger anti-inflammato…
Publications
VST Cells
G-Rex®5M
Publication Date: December 22, 2023
A vital dye-based flow cytometric assay detected the cytolytic activity of multivirus-specific T cells far more reliably than the standard chromium-51 release assay. The cells target five viruses (AdV, BKV, CMV, EBV, HHV6). In seven donors, the 16-hour CFSE assay at a 40:1 effector:target ratio measured specific lysis of at least three to all five viruses, with mean lysis of 9.3% to 28.4%. The 5-hour chromium assay gave heterogeneous, mostly lower values. Sorted CD4+ T cells also killed all five viral targets in the CFSE assay but not in the chromium assay. Optimal co-culture lasted 16 hours, and no non-specific killing of irrelevant or allogeneic targets was seen. PKH26 dye and different…
Publications
CAR T Cells
Publication Date: December 18, 2023
Anti-mesothelin SS1 CAR T-cells carrying a 4-1BBζ endodomain responded more strongly than untransduced T-cells when stimulated through their endogenous T-cell receptor. Retrovirally transduced products from three healthy donors, expanded for 13 days in G-Rex® plates, were compared with untransduced cells and with a signalling-dead zeta-mutant control. After staphylococcal enterotoxin B stimulation, CD8+ 4-1BBζ cells reached a division index of 1.3 versus 0.4 for untransduced cells, 17.4% IFNγ-positive cells versus 6.0%, and 83.4% CD69-positive cells versus 45.2%. Pervanadate-stimulated CD8+ 4-1BBζ cells showed higher phosphorylated ZAP70 (MFI 3104 versus 1643), and their central memory fr…
Publications
CAR T Cells
G-Rex®24 Well Plate, G-Rex®6 Well Plate
Publication Date: December 14, 2023
A dual CAR-T cell pairing a trastuzumab-derived HER2 activating CAR with an inhibitory CAR carrying a LIR1 signaling domain killed HLA-A*02-negative lung cancer cells while sparing their isogenic HLA-A*02-positive counterparts. Screening primary T cells against H1703 targets identified the LIR1 inhibitory domain as the most effective regulator of the activating CAR. Removing the LIR1 D1-D4 Ig motifs raised protection about eightfold, a 30 amino acid hinge proved optimal, and a fully human anti-A2 antibody added about threefold more; protection required both A2 binding and LIR1 signaling. In NSG mice an optimized hinge, humanized or fully human scFv and an IRES linker allowed efficient pro…
Publications
CAR T Cells, TCR T Cells
G-Rex®24 Well Plate
Publication Date: December 13, 2023
Homology-mediated end-joining (HMEJ) enabled Cas9-directed non-viral knock-in of DNA cargo ranging from 1 kb to 6.7 kb into primary human T cells at rates of up to 70% with post-editing viability above 80%. Electroporating the cells 36 hours after CD3/CD28 bead activation, a window named the goldilocks zone, raised integration to 25.7% ±3.5 compared with 5.33% ±1.59 at 24 hours. For a roughly 3 kb transgenic TCR cassette, linearised donor vectors carrying 48 bp homology arms reached 31.35% ±6.12 against 8.40% ±1.76 for homologous recombination. A 6.3 kb five-gene construct yielded 20.1% ±3.43 CD19 CAR-positive cells, rising to 70.3% ±8.66 after methotrexate selection, and these CAR T cell…
Publications
CAR T Cells, T-Cells
G-Rex®6 Well Plate
Publication Date: November 30, 2023
Replacing the extracellular domains of heterodimeric cytokine receptors with leucine zipper motifs produced constitutively active chimeric receptors (ZipRs) that signal without exogenous cytokine. Two zipper motifs were required: Zip2R(2x) drove higher STAT5 phosphorylation, formed larger receptor clusters and kept T cells alive through 7 to 21 days of cytokine starvation, while a single motif did not, and neither construct triggered autonomous growth over 60 days of culture. Zip2R and Zip7R improved B7-H3-CAR and EphA2-CAR T cell expansion and killing across repeated weekly tumor stimulations. In mice bearing intravenous A549 lung tumors, a single subtherapeutic dose of 3 x 10^5 B7-H3-CA…
Publications
CAR T Cells
G-Rex®100M, G-Rex®6M Well Plate
Publication Date: November 29, 2023
A low-cost, point-of-care CAR-T workflow was built around negative T cell selection by red blood cell rosetting, activation, lentiviral transduction and static expansion in G-Rex® vessels. Rosetting of whole blood or quarter leukopak material yielded more than 1 × 10^8 T cells in every donor. Tri-specific CD19/CD20/CD22 CAR-T cells transduced at an MOI of 40 expanded about 35-fold by day 8 in G-Rex®, and replacing the day 3 wash with a 10-fold medium increase did not impair expansion, viability, phenotype or cytotoxicity. Products were dominated by stem-cell memory cells. Scale-up used 1 × 10^8 T cells in a G-Rex® 100M.
Publications
CAR T Cells
Publication Date: November 20, 2023
A bispecific CD33/CD123 CAR built as an AND logic gate controlled acute myeloid leukemia in mice as well as monospecific CD33 or CD123 CARs, while proving less cytotoxic to CD34+ stem cells. Five de novo anti-CD33 and eight anti-CD123 scFv constructs were first screened against engineered CHO target cells, then 32 double-transduced pairings were compared, and 12 single-construct bispecific CARs were built, of which CAR 1 was selected on cytotoxicity, cytokine release and binding avidity. NSG mice bearing 5 × 10^5 MV411 cells received 1 × 10^6 CAR T cells, with no significant survival difference between CAR groups. In humanized CD34+ mice, body weight and blood counts were unchanged, and c…
No manuscripts match your filters.